Bicycle Therapeutics (NASDAQ:BCYC) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 3, Bicycle Therapeutics announced several key leadership transitions as the company enters a new phase of innovation for its proprietary bicyclic peptide technology. Travis Thompson, who joined the firm in 2018 and previously served as senior vice president and chief accounting officer, has been appointed as the new chief financial officer. He succeeds Alethia Young, who will transition into an advisory role after a three-month interim period. Thompson’s new responsibilities include overseeing finance, accounting, and investor relations.
In the clinical and scientific departments, Michael Method, M.D., MPH, MBA, has been promoted to chief medical officer, taking over for Eric Westin, M.D., who is retiring from the role. Dr. Method, an oncologist who joined the company in 2025, will now lead clinical development and manage the Clinical Advisory Board. Additionally, Michael Skynner, Ph.D., a veteran of the company since 2016, is moving from his role as chief technology officer to become the chief scientific officer. Dr. Skynner will focus on scientific discovery, early-stage pipeline development, and the Research & Innovation Advisory Board.
Photo by Pietro Jeng on Pexels
CEO Kevin Lee, Ph.D., stated that these leadership changes are intended to build momentum across the company’s oncology pipeline and create shareholder value following significant progress in 2025. The company highlighted its strengthened operational capacity and a financial runway expected to last into 2028. Moving forward, the executive team aims to advance targeted oncology clinical programs and recently established radiopharmaceutical strategic partnerships to improve patient outcomes.
Bicycle Therapeutics (NASDAQ:BCYC) is a clinical-stage pharmaceutical company that develops a class of medicines for diseases that are underserved by existing therapeutics in the US and the UK.
While we acknowledge the potential of BCYC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.
